[Intraabdominal administration of MMC adsorbed on activated carbon for management of carcinomatous peritonitis].
When Mitomycin C, adsorbed on to activated carbon particles (MMC-CH) was administered intraperitoneally, it was absorbed well by the omentum and peritoneum, and eventually by the lymphatic system. MMC-CH yielded high drug concentrations in intraabdominal tissues and exhibited remarkably low levels in extra-abdominal tissues and peripheral blood. We conducted clinical trials with MMC-CH in 26 patients with carcinomatous peritonitis. High MMC concentrations persisted in ascites, while drug concentrations were extremely low in peripheral blood. Eighteen of the 26 patients studied responded well to MMC-CH and were able to tolerate about 5 times the conventional dose of MMC. Serious adverse effects were not observed, despite the administration of such a large dose.
D000005:Abdomen; D002244:Carbon; D003110:Colonic Neoplasms / Q000150:complications; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000150:complications*; D006801:Humans; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage*; D010051:Ovarian Neoplasms / Q000150:complications; D010538:Peritonitis / Q000188:drug therapy*; D013274:Stomach Neoplasms / Q000150:complications
D008937:Mitomycins; D016685:Mitomycin; D002244:Carbon